Efficacy and Safety of a 4% Hydroquinone Cream for the Treatment of Melasma
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce
melasma on the face, using a split-face randomization design, evaluating the MASI Score from
baseline to week 4 and week 8, in both half-faces receiving active treatment vs. placebo.
To assess the tolerance of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) on the
face.
To assess patients' satisfaction regarding Melanoderm 4% Crema after 8 weeks.